口服薬の静脈内投与後のタルク・グラヌルマトーシスによる肺動脈高血圧: 希少症例報告
Keerthana Nagarajan1, Jacinth Preethi1, Sathya A1
1Department of General Medicine, Government Stanley Medical College & Hospital, Chennai, IND.
Cureus
|August 29, 2025
まとめ
粉砕された錠剤を注射した肺疾患である肺タルコシスは,肺動脈高血圧 (PAH) を引き起こします. 静脈注射薬物使用者の早期発見は 肺の不可逆的な損傷を防ぐために不可欠です
科学分野:
- 肺科
- 毒理学について
- 心臓病科
背景:
- 肺タルコシスは,タルクのような不溶性補助物質の静脈内注射によって引き起こされる珍しい肺疾患です.
- これらの補助物質は肺血管に凝固し,粒状炎症と潜在的に肺動脈高血圧 (PAH) を引き起こします.
研究 の 目的:
- 急性呼吸器障害を呈する肺タルコシスの症例を報告する.
- 静脈内薬物使用と タルクによる肺疾患との関連を強調する
- タルコシスによるPAHの早期診断と介入の重要性を強調する.
主な方法:
- 25歳の男性で 呼吸器の症状が深刻です
- 診断には臨床検査,画像検査 (CTスキャン),心声検査が用いられました.
- 患者さんの病歴は 長期にわたる 静脈内多剤乱用を明らかにした.
主要な成果:
- 患者は呼吸困難,胸の痛み,そして右心筋の緊張の兆候を示しました.
- CTスキャンでは 特徴的な中枢球結が 発現し タルク粒子を検出しました
- タルコシスによる肺高血圧の診断は,臨床的およびイメージングの発見に基づいて確立されました.
結論:
- 肺タルコシスは静脈注射薬の使用の重大な合併症であり,不可逆的なPAHにつながる可能性があります.
- 薬物使用の停止を含む早期の認識と管理は,結果の改善に不可欠です.
- このケースは,原因不明の呼吸器症状とIV薬物乱用歴のある患者のタルコシスを考慮する必要性を強調しています.
関連する概念動画
Pulmonary Tuberculosis I
321
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
321
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
253
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253
Other Pulmonary Disorders
905
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
905
Pulmonary Hypertension: Classification and Pathogenesis
284
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
284
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
247
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
247
Pulmonary Tuberculosis II
343
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
343


